AACR/ASCO JOINT CONFERENCE

Basic and Clinical Aspects of Lymphoma

January 10-14, 1997
Renaissance Esmeralda Resort
Indian Wells (Palm Springs), CA

Supported by a Generous Educational Grant from the
Cure For Lymphoma Foundation
(Corporate Support to be Listed in Future Announcements)

CONFERENCE CO-CHAIRPERSONS

Joseph R. Bertino / New York, NY               James O. Armitage / Omaha, NE

HONORARY CHAIRPERSON

Saul A. Rosenberg / Stanford, CA

PROGRAM COMMITTEE

Franco G. Cavalli / Bellinzona, Switzerland
Raju S. K. Chaganti / New York, NY
Thomas M. Grogan / Tucson, AZ
Ronald Levy / Stanford, CA
Bruce A. Chabner / Boston, MA
Richard I. Fisher / Maywood, IL
Alexandra M. Levine / Los Angeles, CA
Sharon B. Murphy / Chicago, IL

CONFERENCE PROGRAM

Keynote Address
Saul A. Rosenberg / Stanford, CA

The New Entities and Classification
Nancy L. Harris / Boston, MA
Dennis D. Weisenburger / Omaha, NE
James O. Armitage / Omaha, NE
Richard I. Fisher / Maywood, IL

Lymphomagenesis and Etiology
Franco G. Cavalli / Bellinzona, Switzerland
Richard F. Ambinder / Baltimore, MD

Lymphoma Associated with Immunodeficiency
Daniel Knowles / New York, NY
Lode J. Swinnen / Maywood, IL
Alexandra M. Levine / Los Angeles, CA

Genetic Abnormalities in Lymphoma
Raju S. K. Chaganti / New York, NY
Riccardo Dalla-Fevera / New York, NY
Stephan W. Morris / Memphis, TN
Diane C. Louie / New York, NY

Cell Adhesion and Cell Signaling/
Molecular and Homing Receptors
Thomas M. Grogan / Tucson, AZ
Douglas R. Green / San Diego, CA

Can We Improve Outcome with Available Therapies?
Sharon B. Murphy / Chicago, IL
Joseph R. Bertino / New York, NY
John H. Glick / Philadelphia, PA

New Therapies
Bruce A. Chabner / Boston, MA
Oliver W. Press / Seattle, WA
Ronald Levy / Stanford, CA
Richard J. O'Reilly / New York, NY
Finbarr E. Cotter / London, England

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for oral and
poster presentation.

Application Deadline: November 25, 1996

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300    215-440-9313 (FAX)
World Wide Web: http://www.aacr.org
For Young Scientists at the Postdoctoral or Clinical Fellow Level

- **1997 Research Fellowship in Clinical/Translational Research:** This Fellowship, sponsored by Amgen, Inc., will provide a one-year grant of $30,000 to a young scientist in the U.S. or Canada engaged in meritorious clinical or translational cancer research.

- **1997 Research Fellowship in Clinical Research:** This Fellowship, sponsored by Bristol-Myers Squibb Oncology, will provide a one-year grant of $30,000 to a young scientist in the U.S. or Canada engaged in meritorious clinical cancer research.

- **1997 Research Fellowship in Prevention Research:** This Fellowship, sponsored by the Cancer Research Foundation of America, will provide a one-year grant of $30,000 to a young scientist in the U.S. or Canada engaged in meritorious cancer prevention research.

- **1997 Research Fellowships in Basic Research:** Three Fellowships, sponsored by The Sidney Kimmel Foundation for Cancer Research, Hoechst Marion Roussel, and the AACR, will each provide a one-year grant of $30,000 to a young scientist in the U.S. or Canada engaged in meritorious basic cancer research.

- The winners of the Research Fellowships will be announced at the AACR Annual Meeting in San Diego, CA, in April 1997.

**Eligibility**

Candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. Academic faculty holding the rank of assistant professor or higher, graduate or medical students, government employees, and employees of private industry are not eligible. A candidate need not be a member of the AACR at the time of application, but he or she must be nominated by an AACR Member. Associate Members may not be nominators.

**Selection Process**

Applications will receive careful scientific evaluation by a prestigious, multidisciplinary Committee consisting of AACR Members who are experts in basic, clinical, and translational cancer research. Applications must be submitted in complete form by **February 14, 1997.**

**For Further Information/Application Forms**

AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313
e-mail: aacr@aacr.org
AACR SPECIAL CONFERENCE IN CANCER RESEARCH
Disrupted Transcription Factors in Cancer

January 17-21, 1997
Hotel Del Coronado
San Diego, CA

CONFERENCE CHAIRPERSONS
Peter K. Vogt / La Jolla, CA
Frank J. Rauscher, III / Philadelphia, PA

SCIENTIFIC PROGRAM

Keynote Address
Carlo M. Croce / Philadelphia, PA

Basic Transcriptional Mechanisms
Robert Tjian / Berkeley, CA
Danny F. Reinberg / Piscataway, NJ
Arnold J. Berk / Los Angeles, CA

Development, Negative Regulators
Peter Gruss / Gottingen, Germany
David M. Livingston / Boston, MA
Eric N. Olson / Dallas, TX
Stuart Orkin / Boston, MA
Jean Y. J. Wang / La Jolla, CA
Grace Gill / Boston, MA

Solid Tumors I
Gilles Thomas / Paris, France
Christopher T. Denny / Los Angeles, CA
David Ron / New York, NY
Cory Abate-Shen / Piscataway, NJ

Solid Tumors II
Riccardo Dalla Favera / New York, NY
Frederic G. Barr / Philadelphia, PA
Garrett M. Brodeur / Philadelphia, PA
Saraswati Sukumar / Baltimore, MD

Leukemias II
Janet D. Rowley / Chicago, IL
Ronald M. Evans / La Jolla, CA
Paul P. Liu / Ann Arbor, MI
Yoshiaki Ito / Kyoto, Japan
Laurie H. Glimcher / Boston, MA

Clinical Applications
Samuel Waxman / New York, NY
Pier Pelicci / Milan, Italy
Phil Koeffler / Los Angeles, CA

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483

Phone: (215) 440-9300 • Fax: (215) 440-9313
E-mail: aacr@aol.com
AACR web site at http://www.aacr.org
CELL SIGNALING AND CANCER TREATMENT
An American Association for Cancer Research Special Conference
in Collaboration with
Austrian Cancer Society, British Association for Cancer Research,
German Cancer Society and the Austrian Biochemical Society

February 23-28, 1997
Interalpen-Hotel Tyrol
Telfs-Buchen, Austria

CONFERENCE CHAIRPERSONS
Hans H. Grunicke / Innsbruck, Austria
Garth Powis / Tucson, USA
Paul Workman / Macclesfield, England

PROGRAM COMMITTEE
Sara A. Courtneidge / Redwood City, USA
Sylvie Gisselbrecht / Paris, France
Bernd Groner / Freiburg, Germany
Adrian L. Harris / Oxford, England
Peter A. Herrlich / Karlsruhe, Germany
Peter Hilgard / Frankfurt, Germany
Alex Matter / Basel, Switzerland
Frank P. McCormick / Richmond, USA
Laurent Meijer / Roscoff, France
Michael J. Morin / Groton, USA
Axel Ullrich / Munich, Germany

Keynote Address
Paul Workman / Macclesfield, England

Growth Factor Antagonists and Growth Factor Receptor Blockers
Enrique Rozengurt / London, England
Nancy E. Hynes / Basel, Switzerland
Bernd Groner / Freiburg, Germany
Nicholas Lydon / Basel, Switzerland

Receptor and Post Receptor Signaling: Mechanisms and Targets in Cancer Chemotherapy
Sara A. Courtneidge / Redwood City, USA
Frank P. McCormick / Richmond, USA
Nicholas K. Tonks / Cold Spring Harbor, USA
Garth Powis / Tucson, USA
Ulf R. Rapp / Würzburg, Germany
Alan K. Hall / London, England
Axel Ullrich / Munich, Germany

Programmed Cell Death: Role in Oncogenesis and Tumor Therapy
Gerard I. Evan / London, England
Caroline Dive / Manchester, England
Douglas R. Green / La Jolla, USA
Donald W. Nicholson / Pointe-Claire-Dorval, Quebec, Canada

Invasion and Metastasis
Max M. Burger / Basel, Switzerland
Louis F. Reichardt / San Francisco, USA
John G. Collard / Amsterdam, The Netherlands
Helmut Ponta / Karlsruhe, Germany

Angiogenesis
Adrian L. Harris / Oxford, England
Kari K. Alitalo / Helsinki, Finland
Isaiah J. Fidler / Houston, USA

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aol.com
Since its inception in 1973, the Johns Hopkins Oncology Center has been dedicated to improving the understanding of human cancers and finding more effective means of prevention, diagnosis, and treatment. From the outset, programs of the Center were designed to cut across traditional disciplinary lines. A front-runner in this emerging integrated approach to cancer research and care, the Oncology Center became one of the earliest National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. Today, interdisciplinary interactions merge clinical and basic science faculty from 19 departments within the Johns Hopkins University School of Medicine, the School of Hygiene and Public Health, and the School of Nursing, and the Center’s programs extend far beyond the institution, involving investigators from around the world who share scientific interests.

Enhancing this spirit of integration and exchange has been the central mission in planning for the new Johns Hopkins Comprehensive Cancer Center (cover). The new Center, which is currently under construction, will expand existing clinical space and bring together programs and services at Johns Hopkins dedicated to the care of cancer patients. This facility will include operating rooms, surgical beds and support services, and pathology and radiology services, in addition to medical and radiation oncology inpatient and outpatient programs. To pave the way for continued growth in cancer research activities at Johns Hopkins, a state-of-the-art cancer research building also is planned. Currently in the design phase, the new research building will merge cancer research programs and support services and significantly increase the amount of laboratory space devoted to basic research. Both buildings are scheduled for completion in 1998.

The Johns Hopkins Cancer Center comprises six research programs that cut across disciplinary lines: cancer biology, hematologic malignancies, urologic oncology, gastrointestinal cancer, cancer prevention and control, and solid tumor research. The major laboratory activities in the Center span a wide range of studies, including the investigation of the molecular genetics and epidemiology of human cancer; the control of gene transcription; the role of signal transduction pathways in cell growth, differentiation, and apoptosis; molecular aspects of ligand-receptor interaction; the biology of cell renewal and differentiation; cellular response to DNA damage and mechanisms for control of cell cycling activity; abnormalities of DNA methylation and its effect on gene expression; cell structure and cell-cell interaction; and basic aspects of the immune response. Johns Hopkins holds NCI SPORE (Specialized Programs of Research Excellence) grants for prostate, gastrointestinal, and lung cancer and is headquarters of an NCI Brain Tumor Therapy Consortium. In patient care, the Johns Hopkins Cancer Center has emphasized multidisciplinary programs and translational research. Interdisciplinary services are available in breast and colon cancer, cancer prevention and screening, malignant melanoma, and other solid tumors and hematologic malignancies. In 1995, more than 5,200 new patients were seen at the Center.

Major scientific and clinical contributions emanating from the Center include elucidation of the molecular genetics of familial adenomatous polyposis; identification of five genes linked to hereditary nonpolyposis colon cancer; development of the drug 4-HC used to successfully purge tumor cells from the bone marrow; definition of the p53 gene as one of the most frequent changes in tumorigenesis; discovery of the gli gene, which is linked to the development of fatal brain tumors; identification of the association between DNA and the nuclear matrix; clinical development of taxol; identification of the mechanism of action of topoisomerase inhibitors; development of a promising new therapeutic approach in esophageal cancer, using a preoperative drug and radiation therapy regimen; definition of the role of abnormal methylation in causing inactivation of genes during tumor formation; identification of the mechanism of programmed cell death; and discovery of dual chromosome losses in Wilms’ tumor.

The Center’s Director, Martin D. Abeloff (cover), has been deeply committed to translational research throughout his career. Dr. Abeloff’s personal research interests are in the area of therapeutic research in breast and lung tumors, including early dose-intensity studies in lung and breast cancer and clinicopathologic studies that elucidated relationships between small cell and non-small cell lung cancer. He was responsible for the development of the solid tumor clinical research programs in the Oncology Center in the early 1970s, and he has played a leadership role in the development of broad-based research programs in solid tumors, hematologic malignancies, and cancer prevention and control.

Dr. Abeloff received his M.D. from the Johns Hopkins University School of Medicine. He received his Internal Medicine training at the University of Chicago and the Beth Israel Hospital in Boston and his subspecialty training in Oncology and Hematology at the NCI, the Tufts-New England Medical Center, and the Johns Hopkins Oncology Center. Dr. Abeloff joined the faculty of the Johns Hopkins University School of Medicine in 1972 and became a full professor in 1986. He has had an American Cancer Society Clinical Professorship since 1991.

In addition to holding many leadership positions within the Oncology Center and the Johns Hopkins medical institutions, Dr. Abeloff has played a significant leadership role on the national level. He currently serves as Chairperson of the Scientific Advisory Board to the Intramural Division of Clinical Science at the NCI and is a member of the NCI Executive Committee. He has also served as President of the American Society of Clinical Oncology and as Chairperson of the Oncology Drug Advisory Committee of the FDA, and currently he is a member of the Board of Directors of the American Association of Cancer Institutes. He is also a member of the American Association for Cancer Research (AACR). He has been an Associate Editor for the AACR journal Clinical Cancer Research since its inception in 1995, and he has served on the Editorial Board of Cancer Research as well. His other editorial responsibilities include the Editorship of Current Opinion in Oncology and serving as an Associate Editor for the Journal of Clinical Oncology. He is also one of four editors of a new comprehensive textbook of oncology, Clinical Oncology.

Sidney Weinhouse